JPMorgan Initiates Hims & Hers With Overweight: Could the Novo Nordisk Deal Be the Turning Point?

JPMorgan Initiates Hims & Hers With Overweight: Could the Novo Nordisk Deal Be the Turning Point?

The post JPMorgan Initiates Hims & Hers With Overweight: Could the Novo Nordisk Deal Be the Turning Point? appeared first on 24/7 Wall St.. Quick Read JPMorgan initiated Hims & Hers (HIMS) with Overweight and $35 target, citing Novo Nordisk (NVO) partnership as a turning point legitimizing the GLP-1 business. JPMorgan’s endorsement reframes Hims & Hers from a compounded-GLP-1 story into a broader platform play spanning weight loss, women’s he…

Hims & Hers Stock Rallies After JPMorgan Bets On Its GLP-1 Pivot

Hims & Hers shares jumped about 9% Friday after JPMorgan initiated coverage with an overweight rating and a $35 price target. The move comes as Hims announced access to Eli Lilly’s Zepbound and Foundayo through LillyDirect, though the company said it is not affiliated with Lilly. Hims shares recently traded at $30.70. The company serves about 2.5 million subscribers. The post Hims & Hers Stock Rallies After JPMorgan Bets On Its GLP-1 Pivot appea…